Abstract
Molecular radiotherapy (MRT) is founded on the ability to identify or synthesize radionuclide carriers that recognize and bind to tumor-associated target molecules. Advances in our understanding of the molecular biology of cancer and other diseases have identified molecules and signaling pathways that we can now visualize, in vivo, for diagnosis, staging, and to identify optimal therapy and monitor patient response to therapy. These advances have also helped identify targets for
Get full access to this article
View all access options for this article.
